


<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>					Docket No. <b>ABLE-0021</b>	
Applicant(s): <b>Secombes et al.</b>						
Application No. <b>10/088,780</b>	Filing Date <b>July 22, 2002</b>	Examiner <b>Robert M. Kelly</b>	Customer No. <b>26259</b>	Group Art Unit <b>1633</b>	Confirmation No. <b>9521</b>	
Invention: <b>MONOCLONAL ANTIBODY 3F1H10 NEUTRALISING VHSV</b>						
<u>COMMISSIONER FOR PATENTS:</u>						
Transmitted herewith is an amendment in the above-identified application.						
The fee has been calculated and is transmitted as shown below.						
<b>CLAIMS AS AMENDED</b>						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	3 -	52 =	0	x \$50.00	\$0.00	
INDEP. CLAIMS	1 -	4 =	0	x \$200.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>	
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account <b>50-1619</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.						
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>						
 Signature			Dated: <b>January 5, 2007</b>			
<b>Kathleen A. Tyrrell</b> <b>Reg. No. 38,350</b> <b>Licata &amp; Tyrrell P.C.</b> <b>66 E. Main Street</b> <b>Marlton, NJ 08053</b> <b>Tel: 856-810-1515</b> <b>Fax: 856-810-1454</b>			<div style="border: 1px solid black; padding: 5px;">         I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____  <div style="text-align: center;">(Date)</div> </div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> <div style="text-align: center;">Signature of Person Mailing Correspondence</div> <div style="text-align: center; margin-top: 10px;">Typed or Printed Name of Person Mailing Correspondence</div> </div>			
CC:						

RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1633


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ABLE-0021  
Inventors: Secombes et al.  
Serial No.: 10/088,780  
Filing Date: July 22, 2002  
Examiner: Kelly, Robert M.  
Customer No.: 26259  
Group Art Unit: 1633  
Confirmation No.: 9521  
Title: Monoclonal Antibody 3F1H10  
Neutralising VHSV

Electronically Submitted via EFS-Web  
Date: January 5, 2007

I hereby certify that this paper is being electronically  
submitted on the date indicated above to the  
Commissioner for Patents, U.S. Patent &  
Trademark Office (Fee Amendment).

By

  
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents  
U.S. Patent & Trademark Office

Dear Sir:

Reply under 37 C.F.R. 1.116

This is a reply to the Office Action mailed October 5,  
2006 setting a three (3) month statutory period for  
response. Please enter the following amendments and remarks  
into the record.

Attorney Docket No.: **ABLE-0021**  
Inventors: **Secombes et al.**  
Serial No.: **10/088,780**  
Filing Date: **July 22, 2002**  
Page 2

**Amendments to the claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 5.